Zotarolimus (original) (raw)
Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of sirolimus (rapamycin). It was designed for use in stents with phosphorylcholine as a carrier. Zotarolimus, or ABT-578, was originally used on Abbott's coronary stent platforms to reduce early inflammation and restenosis; however, Zotarolimus failed Abbott's primary endpoint to bring their stent/drug delivery system to market. The drug was sold/distributed to Medtronic for use on their stent platforms, which is the same drug they use today. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications associated w
| Property | Value |
|---|---|
| dbo:abstract | Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of sirolimus (rapamycin). It was designed for use in stents with phosphorylcholine as a carrier. Zotarolimus, or ABT-578, was originally used on Abbott's coronary stent platforms to reduce early inflammation and restenosis; however, Zotarolimus failed Abbott's primary endpoint to bring their stent/drug delivery system to market. The drug was sold/distributed to Medtronic for use on their stent platforms, which is the same drug they use today. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications associated with stent use, development of thrombosis which impedes the efficiency of coronary stents, haemorrhagic and restenosis complications are problems associated with stents. These complications have prompted the development of drug-eluting stents. Stents are bound by a membrane consisting of polymers which not only slowly release zotarolimus and its derivatives into the surrounding tissues but also do not invoke an inflammatory response by the body. Medtronic are using zotarolimus as the anti-proliferative agent in the polymer coating of their Endeavor and Resolute products. (en) |
| dbo:casNumber | 221877-54-9 |
| dbo:chEMBL | 1614661 |
| dbo:fdaUniiCode | H4GXR80IZE |
| dbo:kegg | D06669 |
| dbo:pubchem | 9876378 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Zotarolimus.svg?width=300 |
| dbo:wikiPageExternalLink | http://www.lclabs.com/PRODFILE/S-Z/Z-9040.php4 |
| dbo:wikiPageID | 17545599 (xsd:integer) |
| dbo:wikiPageLength | 11863 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 995623940 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Structural_analog dbc:Tetrazoles dbr:Medtronic dbr:Vascular_occlusion dbr:Angiography dbr:Lipophilic dbr:Sirolimus dbr:Stent dbr:Abbott_Laboratories dbc:Immunosuppressants dbr:Drug-eluting_stent dbc:Polyenes dbr:Cardiology dbr:Duplex_ultrasonography dbr:International_Nonproprietary_Name dbc:Macrolides dbr:Tetrazole dbr:Tacrolimus dbr:Phosphorylcholine dbr:FK_binding_protein-12 dbr:Immunosuppressant dbr:Rapamycin dbr:Octanol-water_partition_coefficient dbr:Restenosis dbr:Thrombosis dbr:Drug-eluting_stents dbr:Hydroxyl_group dbr:Anti-proliferative |
| dbp:atcPrefix | None (en) |
| dbp:c | 52 (xsd:integer) |
| dbp:casNumber | 221877 (xsd:integer) |
| dbp:chembl | 1614661 (xsd:integer) |
| dbp:chemspiderid | 21468821 (xsd:integer) |
| dbp:h | 79 (xsd:integer) |
| dbp:iupacName | -927 (xsd:integer) |
| dbp:kegg | D06669 (en) |
| dbp:molecularWeight | 966.210000 (xsd:double) |
| dbp:n | 5 (xsd:integer) |
| dbp:o | 12 (xsd:integer) |
| dbp:pubchem | 9876378 (xsd:integer) |
| dbp:smiles | CC1CCC2CCOC (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | CGTADGCBEXYWNE-JUKNQOCSSA-N (en) |
| dbp:synonyms | -42 (xsd:integer) |
| dbp:unii | H4GXR80IZE (en) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Reflist dbt:Fdacite dbt:Immunosuppressants |
| dcterms:subject | dbc:Tetrazoles dbc:Immunosuppressants dbc:Polyenes dbc:Macrolides |
| gold:hypernym | dbr:Immunosuppressant |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Immunosuppressant103562958 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 yago:WikicatImmunosuppressants dbo:Drug yago:Substance100020090 umbel-rc:DrugProduct |
| rdfs:comment | Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of sirolimus (rapamycin). It was designed for use in stents with phosphorylcholine as a carrier. Zotarolimus, or ABT-578, was originally used on Abbott's coronary stent platforms to reduce early inflammation and restenosis; however, Zotarolimus failed Abbott's primary endpoint to bring their stent/drug delivery system to market. The drug was sold/distributed to Medtronic for use on their stent platforms, which is the same drug they use today. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications associated w (en) |
| rdfs:label | Zotarolimus (en) |
| owl:sameAs | freebase:Zotarolimus yago-res:Zotarolimus wikidata:Zotarolimus dbpedia-sh:Zotarolimus dbpedia-sr:Zotarolimus dbpedia-vi:Zotarolimus https://global.dbpedia.org/id/Xz1P |
| prov:wasDerivedFrom | wikipedia-en:Zotarolimus?oldid=995623940&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Zotarolimus.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Zotarolimus |
| is dbo:wikiPageWikiLink of | dbr:List_of_compounds_with_carbon_numbers_50+ dbr:Percutaneous_coronary_intervention dbr:MTOR_inhibitors dbr:Dual_therapy_stent dbr:Phosphorylcholine dbr:List_of_signaling_peptide/protein_receptor_modulators dbr:List_of_drugs:_Z |
| is foaf:primaryTopic of | wikipedia-en:Zotarolimus |
